Outcomes in Systemic Sclerosis–Associated Interstitial Lung Disease Based on Serological Profiles With a Focus on Anticentromere and Anti-RNA Polymerase III Antibodies
These analyses of data from the SENSCIS trial suggest that patients with SSc-ILD who are ACA positive or ARA positive can experience progression of SSc-ILD. Patients negative for ACA, ARA, and ATA had a higher rate of progression than the overall trial population and should be monitored closely.
Authors
- Elizabeth R. Volkmann (ORCID: https://orcid.org/0000-0003-3750-6569)
- Rozeta Simonovska
- Shervin Assassi (ORCID: https://orcid.org/0000-0002-8059-9978)
- Steven Sambevski
- Elana J. Bernstein (ORCID: https://orcid.org/0000-0001-5560-6390)
- Christopher P. Denton
- Margarida Alves
Institutions
- University of California, Los Angeles (US)
- Boehringer Ingelheim (China) (CN)
- Tissue Dynamics (Israel) (IL)
- Q Bioanalytic (Germany) (DE)
- The University of Texas Health Science Center (US)
- University College London (GB)
- Columbia University (US)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2025-04-15
- DOI
- https://doi.org/10.3899/jrheum.2024-1063
- Citations
- 4
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 5.89
Funders
- GlaxoSmithKline